Monday 19 October 2026 / Nouscom
Nouscom
Nouscom develops off-the-shelf neoantigen-based cancer immunotherapies, led by its lead asset NOUS-209 for cancer interception in Lynch Syndrome carriers.
Basel, SwitzerlandBiotech & pharmanouscom.com
$135.0M
Series D, 19 October
Lead investorM-Ventures, Revelation Partners
Other investors5AM Ventures, Andera Partners, Angelini Industries, Angelini Investments, Angelini Ventures, Aurea, Bpifrance, CDP Venture Capital, EIB, EQT Life Sciences, European Investment Bank, Indaco Venture Partners, Neva SGR, Panakes Partners, Versant Ventures, XGEN Ventures
Reported by12 sources
What makes it different
Its lead asset NOUS-209 targets dMMR/MSI tumours with 209 shared frameshift peptide neoantigens and is aimed at preventing cancer in Lynch Syndrome carriers, with FDA Fast Track designation.
Nouscom develops off-the-shelf neoantigen-based cancer immunotherapies, led by its lead asset NOUS-209 for cancer interception in Lynch Syndrome carriers.
Founders
MU
Marina Udier
CEO
MU
Marina Udier
Chief Executive
MU
Marina Udier
Chief Executive Officer
GA
Göran Ando
Independent Chairman of the Board
Funding history
Monday 19 October 2026
$135.0M Series D, led by M-Ventures, Revelation Partners